Top

Published in:

Open Access 01-04-2017 | Original Article

Microparticles in patients undergoing transcatheter aortic valve implantation (TAVI)

Authors: Christian Jung, Michael Lichtenauer, Hans-Reiner Figulla, Bernhard Wernly, Bjoern Goebel, Martin Foerster, Christoph Edlinger, Alexander Lauten

Published in: Heart and Vessels | Issue 4/2017

Abstract

Degenerative aortic stenosis (AS) is the most frequent form of acquired valvular heart disease. AS is known to entail endothelial dysfunction caused by increased mechanical shear stress leading to elevated circulatory levels of microparticles. Endothelial and platelet microparticles (EMP and PMP) are small vesicles that originate from activated cells and thrombocytes. We sought to evaluate whether transcatheter aortic valve implantation (TAVI) procedure would elicit effects on circulating EMP and PMP. 92 patients undergoing TAVI procedure for severe AS were included in this study. Samples were obtained at each visit before TAVI, 1 week post-procedure and at 1, 3 and after 6 months after TAVI and were evaluated using flow cytometry. A 12 month clinical follow-up was also performed. CD62E+ EMP concentration before TAVI was 21.11 % (±6.6 % SD) and declined to 20.99 % (±6.8 % SD) after 1 week, to 16.63 % (±5.4 % SD, p < 0.0001) after 1 month, to 17.08 % (±4.6 % SD, p < 0.0001) after 3 months and to 15.94 % (±5.4 % SD, p < 0.0001) after 6 months. CD31+/CD42b−, CD31+/Annexin+/− EMP remained unchanged. CD31+/CD41b+ PMP evidenced a slight, but statistically significant increase after TAVI and remained elevated during the entire follow-up. Apart from a procedure-related improvement in echocardiographic parameters, TAVI procedure led also to a decline in CD62E+ EMP. The reduction in pressure gradients with less hemodynamic shear stress seems also to have beneficially affected endothelial homeostasis.

Available only for authorised users

Lindman BR, Bonow RO, Otto CM (2013) Current management of calcific aortic stenosis. Circ Res 113:223–237CrossRefPubMedPubMedCentral

Stolker JM, Patel AY, Lim MJ, Hauptman PJ (2013) Estimating the adoption of transcatheter aortic valve replacement by us interventional cardiologists and clinical trialists. Clin Cardiol 36:691–697CrossRefPubMed

Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M (2006) Burden of valvular heart diseases: a population-based study. Lancet 368:1005–1011CrossRefPubMed

Horne A Jr, Reineck EA, Hasan RK, Resar JR, Chacko M (2014) Transcatheter aortic valve replacement: historical perspectives, current evidence, and future directions. Am Heart J 168:414–423CrossRefPubMed

Galeone A, Paparella D, Colucci S, Grano M, Brunetti G (2013) The role of tnf-alpha and tnf superfamily members in the pathogenesis of calcific aortic valvular disease. ScientificWorldJournal 2013:875363CrossRefPubMedPubMedCentral

Yutzey KE, Demer LL, Body SC, Huggins GS, Towler DA, Giachelli CM, Hofmann-Bowman MA, Mortlock DP, Rogers MB, Sadeghi MM, Aikawa E (2014) Calcific aortic valve disease: a consensus summary from the alliance of investigators on calcific aortic valve disease. Arterioscler Thromb Vasc Biol 34:2387–2393CrossRefPubMedPubMedCentral

Kapadia SR, Yakoob K, Nader S, Thomas JD, Mann DL, Griffin BP (2000) Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 36:208–212CrossRefPubMed

Ferrari G, Sainger R, Beckmann E, Keller G, Yu PJ, Monti MC, Galloway AC, Weiss RL, Vernick W, Grau JB (2010) Validation of plasma biomarkers in degenerative calcific aortic stenosis. J Surg Res 163:12–17CrossRefPubMedPubMedCentral

Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, Rukh G, Dufresne L, Almgren P, Owens DS, Harris TB, Peloso GM, Kerr KF, Wong Q, Smith AV, Budoff MJ, Rotter JI, Cupples LA, Rich S, Kathiresan S, Orho-Melander M, Gudnason V, O’Donnell CJ, Post WS, Thanassoulis G (2014) Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA 312:1764–1771CrossRefPubMedPubMedCentral

10.

Cappabianca G, Ferrarese S, Musazzi A, Terrieri F, Corazzari C, Matteucci M, Beghi C (2016) Predictive factors of long-term survival in the octogenarian undergoing surgical aortic valve replacement: 12-year single-centre follow-up. Heart Vessels. doi:10.1007/s00380-016-0804-3 PubMed

11.

Shim BJ, Lee DH, Youn HJ (2014) Increased soluble vascular adhesion molecule-1 concentration is associated with impaired coronary flow reserve in cardiac syndrome x. Heart Vessels 29:723–731CrossRefPubMed

12.

Lichtenauer M, Goebel B, Fritzenwanger M, Forster M, Betge S, Lauten A, Figulla HR, Jung C (2015) Simulated temporary hypoxia triggers the release of cd31+/annexin+ endothelial microparticles: a prospective pilot study in humans. Clin Hemorheol Microcirc 61:83–90CrossRefPubMed

13.

Jung C, Sorensson P, Saleh N, Arheden H, Ryden L, Pernow J (2012) Circulating endothelial and platelet derived microparticles reflect the size of myocardium at risk in patients with st-elevation myocardial infarction. Atherosclerosis 221:226–231CrossRefPubMed

14.

Montoro-Garcia S, Shantsila E, Wrigley BJ, Tapp LD, Abellan Aleman J, Lip GY (2015) Small-size microparticles as indicators of acute decompensated state in ischemic heart failure. Rev Esp Cardiol (Engl Ed) 68:951–958CrossRef

15.

Jung C, Rafnsson A, Shemyakin A, Bohm F, Pernow J (2010) Different subpopulations of endothelial progenitor cells and circulating apoptotic progenitor cells in patients with vascular disease and diabetes. Int J Cardiol 143:368–372CrossRefPubMed

16.

Jung C, Drummer K, Oelzner P, Figulla HR, Boettcher J, Franz M, Betge S, Foerster M, Wolf G, Pfeil A (2015) The association between endothelial microparticles and inflammation in patients with systemic sclerosis and raynaud’s phenomenon as detected by functional imaging. Clin Hemorheol Microcirc 61(3):549–557CrossRefPubMed

17.

Satta N, Toti F, Feugeas O, Bohbot A, Dachary-Prigent J, Eschwege V, Hedman H, Freyssinet JM (1994) Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide. J Immunol 153:3245–3255PubMed

18.

Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, Mutin M, Sanmarco M, Sampol J, Dignat-George F (1999) In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 104:93–102CrossRefPubMedPubMedCentral

19.

Jung C, Lichtenauer M, Wernly B, Franz M, Goebel B, Rafnsson A, Figulla HR, Pernow J (2016) Effect of endothelin-1 and endothelin receptor blockade on the release of microparticles. Eur J Clin Invest 46(8):707–713. doi:10.1111/eci.12652 CrossRefPubMed

20.

Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A (2009) Endothelial microparticles in diseases. Cell Tissue Res 335:143–151CrossRefPubMed

21.

Feng B, Chen Y, Luo Y, Chen M, Li X, Ni Y (2010) Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 208:264–269CrossRefPubMed

22.

Koga H, Sugiyama S, Kugiyama K, Watanabe K, Fukushima H, Tanaka T, Sakamoto T, Yoshimura M, Jinnouchi H, Ogawa H (2005) Elevated levels of ve-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 45:1622–1630CrossRefPubMed

23.

Abrams CS, Ellison N, Budzynski AZ, Shattil SJ (1990) Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 75:128–138PubMed

24.

Bal L, Ederhy S, Di Angelantonio E, Toti F, Zobairi F, Dufaitre G, Meuleman C, Mallat Z, Boccara F, Tedgui A, Freyssinet JM, Cohen A (2010) Factors influencing the level of circulating procoagulant microparticles in acute pulmonary embolism. Arch Cardiovasc Dis 103:394–403CrossRefPubMed

25.

Horn P, Stern D, Veulemans V, Heiss C, Zeus T, Merx MW, Kelm M, Westenfeld R (2015) Improved endothelial function and decreased levels of endothelium-derived microparticles after transcatheter aortic valve implantation. EuroIntervention 10:1456–1463CrossRefPubMed

26.

Pirro M, Schillaci G, Paltriccia R, Bagaglia F, Menecali C, Mannarino MR, Capanni M, Velardi A, Mannarino E (2006) Increased ratio of cd31+/cd42− microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol 26:2530–2535CrossRefPubMed

27.

Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium-2 consensus document. Eur Heart J 33:2403–2418CrossRefPubMed

28.

Biancari F, Barbanti M, Santarpino G, Deste W, Tamburino C, Gulino S, Imme S, Di Simone E, Todaro D, Pollari F, Fischlein T, Kasama K, Meuris B, Dalen M, Sartipy U, Svenarud P, Lahtinen J, Heikkinen J, Juvonen T, Gatti G, Pappalardo A, Mignosa C, Rubino AS (2016) Immediate outcome after sutureless versus transcatheter aortic valve replacement. Heart Vessels 31:427–433CrossRefPubMed

29.

Shantsila E, Kamphuisen PW, Lip GY (2010) Circulating microparticles in cardiovascular disease: implications for atherogenesis and atherothrombosis. J Thromb Haemost 8:2358–2368CrossRefPubMed

30.

Lee ST, Chu K, Jung KH, Kim JM, Moon HJ, Bahn JJ, Im WS, Sunwoo J, Moon J, Kim M, Lee SK, Roh JK (2012) Circulating cd62e+ microparticles and cardiovascular outcomes. PLoS One 7:e35713CrossRefPubMedPubMedCentral

31.

Diehl P, Nagy F, Sossong V, Helbing T, Beyersdorf F, Olschewski M, Bode C, Moser M (2008) Increased levels of circulating microparticles in patients with severe aortic valve stenosis. Thromb Haemost 99:711–719PubMed

32.

Vion AC, Ramkhelawon B, Loyer X, Chironi G, Devue C, Loirand G, Tedgui A, Lehoux S, Boulanger CM (2013) Shear stress regulates endothelial microparticle release. Circ Res 112:1323–1333CrossRefPubMed

33.

Dabagh M, Vasava P, Jalali P (2015) Effects of severity and location of stenosis on the hemodynamics in human aorta and its branches. Med Biol Eng Comput 53:463–476CrossRefPubMed

34.

Rouleau L, Copland IB, Tardif JC, Mongrain R, Leask RL (2010) Neutrophil adhesion on endothelial cells in a novel asymmetric stenosis model: effect of wall shear stress gradients. Ann Biomed Eng 38:2791–2804CrossRefPubMedPubMedCentral

35.

Franca CN, Pinheiro LF, Izar MC, Brunialti MK, Salomao R, Bianco HT, Kasmas SH, Barbosa SP, de Nucci G, Fonseca FA (2012) Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J 76:729–736CrossRefPubMed

36.

Makkar RR, Fontana G, Jilaihawi H, Chakravarty T, Kofoed KF, de Backer O, Asch FM, Ruiz CE, Olsen NT, Trento A, Friedman J, Berman D, Cheng W, Kashif M, Jelnin V, Kliger CA, Guo H, Pichard AD, Weissman NJ, Kapadia S, Manasse E, Bhatt DL, Leon MB, Sondergaard L (2015) Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med 373:2015–2024CrossRefPubMed

37.

Pache G, Schoechlin S, Blanke P, Dorfs S, Jander N, Arepalli CD, Gick M, Buettner HJ, Leipsic J, Langer M, Neumann FJ, Ruile P (2015) Early hypo-attenuated leaflet thickening in balloon-expandable transcatheter aortic heart valves. Eur Heart J. doi:10.1093/eurheartj/ehv526 PubMed

38.

Sinning JM, Losch J, Walenta K, Bohm M, Nickenig G, Werner N (2011) Circulating cd31+/annexin v+ microparticles correlate with cardiovascular outcomes. Eur Heart J 32:2034–2041CrossRefPubMed

39.

Gwechenberger M, Hulsmann M, Berger R, Graf S, Springer C, Stanek B, Pacher R (2004) Interleukin-6 and b-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transplant 23:839–844CrossRefPubMed

40.

Gwechenberger M, Mendoza LH, Youker KA, Frangogiannis NG, Smith CW, Michael LH, Entman ML (1999) Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 99:546–551CrossRefPubMed

Title: Microparticles in patients undergoing transcatheter aortic valve implantation (TAVI)
Authors: Christian Jung
Michael Lichtenauer
Hans-Reiner Figulla
Bernhard Wernly
Bjoern Goebel
Martin Foerster
Christoph Edlinger
Alexander Lauten
Publication date: 01-04-2017
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 4/2017
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-016-0885-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Microparticles in patients undergoing transcatheter aortic valve implantation (TAVI)

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2017

Prediction of 1-year clinical outcomes using the SYNTAX score in patients with prior heart failure undergoing percutaneous coronary intervention: sub-analysis of the SHINANO registry

Selvester QRS score and total perfusion deficit calculated by quantitative gated single-photon emission computed tomography in patients with prior anterior myocardial infarction in the coronary intervention era

The side-to-side fashion for individual distal coronary anastomosis using venous conduit

Higher hemoglobin A1c levels are associated with impaired left ventricular diastolic function and higher incidence of adverse cardiac events in patients with nonischemic dilated cardiomyopathy

Comparison of salt with low-dose furosemide and carperitide for treating acute decompensated heart failure: a single-center retrospective cohort study

Are atherosclerotic risk factors associated with a poor prognosis in patients with hyperuricemic acute heart failure? The evaluation of the causal dependence of acute heart failure and hyperuricemia

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page